An Open-label, Fixed Sequence Study to Assess the Effect of Multiple Doses of Baxdrostat on the Pharmacokinetics of Single Doses of Combined Oral Ethinyl Estradiol and Levonorgestrel in Healthy Female Participants of Non-childbearing Potential.

The article discusses a clinical trial, NCT06657105, conducted by AstraZeneca to assess the effect of multiple doses of baxdrostat on the pharmacokinetics of a single dose of combined oral ethinyl estradiol and levonorgestrel in healthy female participants of non-childbearing potential. The study aims to evaluate the safety and tolerability of baxdrostat during the trial period. The trial is set to be completed by January 17, 2025, and will involve 48 participants. The study design is interventional, with a non-randomized allocation and a sequential intervention model. [Extracted from the article]